Radiopharm Theranostics Stock Price, News & Analysis

Radiopharm Theranostics Limited (NASDAQ: RADX, ASX: RAD) is a clinical-stage biopharmaceutical company focused on oncology radiopharmaceuticals for diagnostic and therapeutic applications in areas of high unmet medical need. According to company disclosures, Radiopharm is developing a platform of radiotherapeutic and imaging agents that span peptides, small molecules, and monoclonal antibodies for use in a variety of solid tumor cancers, including lung, breast, and brain metastases.

Business focus and core pipeline

Radiopharm describes itself as a clinical stage radiotherapeutics company with a pipeline of distinct and highly differentiated platform technologies. Its programs combine targeting molecules such as small molecules, nanobodies and monoclonal antibodies with medical radioisotopes to either visualize or treat cancer. Company communications repeatedly note that the clinical program includes one Phase 2 trial and multiple Phase 1 trials across solid tumors.

A central element of the pipeline is 18F‑RAD101, a novel imaging small molecule that targets fatty acid synthase (FASN), a multi‑enzyme protein overexpressed in many solid tumors, including cerebral metastases. RAD101 is radiolabelled with Fluorine‑18 and is being evaluated in a U.S. Phase 2b clinical imaging trial in individuals with suspected or recurrent brain metastases from solid tumors of different origins. Company updates state that RAD101 has received U.S. Food and Drug Administration (FDA) Fast Track Designation to distinguish between recurrent disease and treatment effect in brain metastases.

Radiopharm is also advancing several Lutetium‑177 (177Lu) based radiotherapeutic candidates. 177Lu‑RAD202 is a single‑domain monoclonal antibody (sdAb) targeting HER2‑positive advanced solid tumors and is being evaluated in the Phase 1 ‘HEAT’ dose‑escalation trial. HER2 is described by the company as a validated target in oncology, with RAD202 having previously shown clinical proof‑of‑concept and favorable safety and biodistribution in a diagnostic study of HER2‑positive breast cancer patients.

177Lu‑RAD204 is another nanobody‑based radiotherapeutic targeting PD‑L1, a protein overexpressed in many solid cancers. It is being studied in a Phase 1 trial in PD‑L1‑positive advanced cancers, including non‑small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple‑negative breast cancer (TNBC), cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC) and endometrial cancer. Company reports highlight that early clinical data have shown tumor uptake in PD‑L1‑positive lesions and a favorable safety profile at initial dose levels.

Additional clinical and preclinical programs

Beyond these lead assets, Radiopharm is developing Ga68‑RAD301, a peptide targeting αvβ6‑integrin radiolabelled with Gallium‑68, in a Phase 1 imaging trial in pancreatic ductal adenocarcinoma (PDAC). The αvβ6‑integrin is described as a cellular marker for tumor invasion and metastatic growth, with RAD301 having received Orphan Drug Designation from the FDA for pancreatic cancer.

The company is also progressing RAD402, an anti‑KLK3 monoclonal antibody radiolabelled with the radionuclide 161Tb for the treatment of metastatic or locally advanced prostate cancer. According to Radiopharm, RAD402 binds kallikrein related peptidase 3 (KLK3), which encodes prostate specific antigen (PSA), and has shown strong tumor targeting and a biodistribution profile consistent with monoclonal antibodies in preclinical models. Human Research Ethics Committee approval in Australia has been granted to initiate a first‑in‑human Phase 1 clinical trial in advanced prostate cancer.

Through Radiopharm Ventures, LLC, a joint venture with The University of Texas MD Anderson Cancer Center, Radiopharm is developing RV‑01 (Betabart), a Lu177‑B7H3 monoclonal antibody. Company announcements describe RV‑01 as designed with strong affinity for the 4Ig isoform of B7H3, which is highly expressed in tumors and not in healthy tissues. The U.S. FDA has cleared an Investigational New Drug (IND) application for RV‑01, enabling a Phase 1 first‑in‑human therapeutic trial in multiple solid tumors.

Theranostic approach and oncology focus

Radiopharm emphasizes a theranostic strategy, combining diagnostic imaging agents and therapeutic radiopharmaceuticals built on shared biological targets. For example, RAD101 is used for imaging brain metastases, while other agents such as RAD202, RAD204, RAD301, RAD402 and RV‑01 are developed as therapeutics or imaging tools for specific tumor‑associated targets including FASN, HER2, PD‑L1, αvβ6‑integrin, KLK3 and B7H3. Across its disclosures, the company highlights applications in brain metastases, lung cancer, breast cancer, pancreatic cancer, prostate cancer and other solid tumors.

Radiopharm’s communications consistently describe its goal as developing radiopharmaceutical products for cancer treatment and diagnosis in areas where existing options are limited. Its programs cover both imaging trials that assess diagnostic performance and therapeutic trials that evaluate safety, biodistribution, dosimetry and preliminary anti‑tumor activity.

Corporate profile and listings

Radiopharm Theranostics Limited is an Australian‑based company with its principal executive office located in Victoria, Australia, as disclosed in its SEC filings. The company’s ordinary shares trade on the Australian Securities Exchange (ASX: RAD), and its securities are also listed on the Nasdaq under the ticker RADX. As a foreign private issuer, Radiopharm files reports on Form 20‑F and Form 6‑K with the U.S. Securities and Exchange Commission, often furnishing Australian Securities Exchange announcements as exhibits.

Company announcements describe Radiopharm as having entered supply agreements for key radioisotopes, including non‑carrier‑added Lutetium‑177 and Terbium‑161, to support clinical trials of its Lutetium‑ and Terbium‑based molecules. Radiopharm has also reported capital raisings via institutional placements and share purchase plans to fund drug manufacturing, clinical trials and working capital.

Regulatory and clinical development environment

Radiopharm’s disclosures highlight multiple regulatory interactions, including FDA Fast Track Designation for RAD101 and IND clearance for RV‑01. Ethics approvals in Australia, such as Bellberry Human Research Ethics Committee approval for RAD402, support first‑in‑human studies in that jurisdiction. The company’s trials are described as multi‑center, open‑label and dose‑escalation or single‑arm imaging studies, reflecting typical early‑stage oncology radiopharmaceutical development.

Across its pipeline, Radiopharm reports early clinical data such as tumor uptake, safety signals and stable disease observations, which it uses to justify progression to higher dose levels or later‑stage trials. For example, data from initial cohorts in the RAD202 and RAD204 programs have supported dose escalation, while interim RAD101 imaging data have demonstrated concordance with MRI in brain metastases.

Position within healthcare and biotechnology

Within the broader healthcare sector, Radiopharm is categorized as a biotechnology company focused on radiotherapeutics and radiopharmaceutical imaging in oncology. Its activities span research, development and planned commercialization of health technologies, as reflected in earlier descriptions of the company as being engaged in research, development and commercialization of health technologies. By concentrating on radiolabelled agents targeting tumor‑associated proteins and receptors, Radiopharm operates at the intersection of nuclear medicine, oncology and molecular imaging.

Key themes for investors and observers

Investors and observers reviewing Radiopharm Theranostics typically focus on:

• The progress and outcomes of its Phase 2b RAD101 imaging trial in brain metastases and associated regulatory designations.
• Safety, biodistribution and early efficacy data from Phase 1 therapeutic trials of 177Lu‑RAD202, 177Lu‑RAD204 and future trials of RV‑01 and RAD402.
• Development of RAD301 in pancreatic cancer imaging and its Orphan Drug Designation status.
• Capital raising activities and reported cash runway to support ongoing clinical programs.
• Collaborations such as the Radiopharm Ventures joint venture with MD Anderson Cancer Center for B7H3‑targeted radiopharmaceuticals.

According to its own announcements, Radiopharm aims to build a platform of radiopharmaceutical products that can be applied across multiple solid tumor types, using both diagnostic and therapeutic modalities to address high unmet medical needs in oncology.